Introduction
Human cytomegalovirus (HCMV) belongs to the family Herpesviridae. It is an opportunistic pathogen for individuals with a compromised or immature immune system after primary infection; it leads to a lifelong latency among 40-90% of adults. HCMV has the most significant impact on immune-compromised hematopoietic stem cell transplant recipients, individuals with HIV infection, and congenitally infected neonates [1] [2] [3] .
Systemic HCMV infection may be treated with a few approved CMV inhibitors such as ganciclovir (GCV), cidofovir, foscarnet, and maribavir (MBV); treatment failure is common because of specific mutations within a subset of HCMV genes [4] . Variations in 3 UL97 (code for phosphotransferase), UL54 (DNA polymerase), and UL27 (nuclear protein) genes are responsible for all single or multi-drug resistance [5] [6] [7] . The frequency of drugresistant clinical and laboratory strains has driven attempts to the development of novel anti-CMV compounds [8] .
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low toxicity, which directly targets viral kinase UL97 and nuclear egress [9] . Identification of MBV resistance mutations in laboratory strains with variations on one of early viral transcript products, UL27 (pUL27), suggests that pUL27 may have a role in nuclear egress whereas it has no critical role in viral replication, and it may have a quiet conflicting function by regulating pUL97 [7, 10] . UL27 represents an early transcript of CMV replication phase, and it is also thought to be a substrate for phosphorylation by viral kinase, pUL97 [7] . Further study on pUL27 revealed its role on the infected host cell cycle arrest by direct targeting Tip60 for degradation [11] . Studies on pUL27 are few and ongoing. It is predicted that pUL27 may have four conserved regions [12] .
We aimed to determine if there are any polymorphism(s) in pUL27 N-terminal coding sequence among samples from patients not treated with MBV, with congenital disease, and HIV infection in Iran. Polymorphisms in UL27 were found more frequently in the setting of HIV infection.
Materials and Methods

Sample Preparations
The aim of this molecular study was to investigate pUL27 polymorphism among two at-CMV risk groups of patients. We studied 20 CMV-positive samples provided by our previous study [13] . Briefly, DNA of 2,000 samples from neonates with congenital disease and 180 HIV-infected patients have been extracted by boiling procedure and checked for CMV infection by using polymerase chain reaction (PCR) [14] .
PCR Assay
Amplification of CMV DNA in the samples was performed in a total volume of 25 μl. The reaction mixture consisted of 1× reaction buffer, 5 m M MgCl 2 , 100 μ M of each deoxynucleotide triphosphate (dNTP), 2.5 units of Hot start Taq DNA polymerase (GeNetBio, Korea), and 10 p M of each forward and reverse primers [15] . Initial denaturation at 94 ° C for 5 min, followed by 35 cycles of 94, 55, and 72 ° C all for 1 min with final extension at 72 ° C for 5 min was the thermal protocol. Generated amplicons with a 702 bp size were analyzed by 1/5% agarose gel electrophoresis containing SYBER ® green staining. Twenty positive samples were sent for DNA sequencing (Macrogen, South Korea). Results were aligned by reference sequence AD169 (protein ID: CAA35426.1) using BLASTx.
Statistical Analysis
Statistical analysis was performed by SPSS 16.0.0. The χ 2 test (95% CIs) was used for investigating the relation between type of diseases and pUL27 polymorphisms.
Ethical Approval
This study was approved by Golestan University of Medical Sciences Ethical committee, approval code of: 31078693122446.
Results
Of 20 total samples, 5% of HIV patients (9/180) and 0.55% of congenitally infected neonates (11/2,000) were CMV positive. All CMV-positive samples were amplified for UL27 Products with 702 bp size encompassing nucleotide 33894 to 34595 (coding for amino acids E22 to T254) of reference sequence AD169 (GenBank: X17403.1) Sample products were then sequenced (Macrogen, Korea). DNA sequences were submitted to GenBank with the following accession numbers: KY173011, KY173012, KY173013, KY173014, KY173015, KY173016, KY173017, KY173018, KY173019, KY173020 for congenital, and KY173021, KY173022, KY173023, KY173024, KY173025, KY173026, KY173027, KY173028, KY173029 for HIV infection.
As UL27 is conserved among β-herpesviruses, we used AD169 UL27 coding sequence for multiple sequence alignment by Clustal Omega, then good quality sequenced nucleotides were chosen for BLASTx. As shown in Table 1 , there was a significant relation between the frequency of polymorphism and the type of disease, and it was higher in HIV-infected patients than in infected neonates (55.5: 9.1%; p < 0.05). In contrast, our results did not show any relation between frequency of each single polymorphism and the type of disease. K90 polymorphism was most prevalent (15%) in both HIV and congenitally infected patients. Mutations of Q54, D123, and R107 (10%) were seen in more than one sample. All substitutions are presented in Table 1 . There was also a guanine 231 insertion into an HIV-infected sample causing a truncated pUL27 protein containing 76 amino acids. Ninety-one percent of congenitally and 44.4% of HIV-infected CMVpositive samples had no mutations in respective amplified UL27 coding sequence relative to AD169.
There was only one congenitally CMV-positive neonate that shared a substitution in the HIV patient cohort ( Table 1 ) . Demographic results of HIV-infected patients are obtained from a previous study by our group [16] . There was no relationship between CD4 counts and pUL27 variation. Additionally, no relation was observed between CD4 counts and type of amino acid polymorphism in this group. Furthermore, any other parameters shown in Table 2 had no relation, but there was a significant correlation between high active anti-retroviral therapy and pUL27 R107 variation ( p = 0.003).
HCMV-positive neonates were from 3 Persian (6/11), Turkmen (3/11), and Sistanian (2/11) ethnicities. The patients were examined for disease manifestations, including hepatomegaly, hydrocephaly, microcephaly, and eye abnormalities. No congenitally infected neonates had either disease manifestations or a history of anti-CMV drug treatment. Neither demographical nor disease manifestations had any relation with pUL27 variations.
Discussion
In accordance with published prevalence of CMV among neonates (0.6%; 6/1,000) [17] , we found that CMV incidence rate was 0.55% (5.5/1,000) in infants from north of Iran. Among congenitally CMV-infected infants as well as HIV-positive patients, we investigated the frequency of UL27 sequence polymorphism. Previous studies preferentially studied UL27 mutations under diverse MBV concentration with or without pUL97 function. The N-terminal region of pUL27 includes a few known MBV mutations like E22 stop and R233S [12] . Therefore, we aimed to explore any potential variation of pUL27 5 ′ amino terminal region in the setting of CMV infection under host pressure and HIV infection.
Our results have shown that the incidence rate of UL27 polymorphisms is significantly higher in HIV-infected patients than those congenitally infected. This indicates that pUL27 may have functions potentiated under HIV-CMV co-infection. In common, with recently shown frequent pUL27 polymorphisms in immunocompromised patients [18] , we found new polymorphisms in HIV-infected patients. As shown in Table 2 , almost 67% of HIVpositive individuals had progressed to AIDS and are No polymorphisms were observed in the majority of congenitally infected HCMV-positive neonates. This suggests an early infection with the virus, where polymorphisms have not had time to accrue. On the contrary, in one neonate, pUL27 polymorphisms were observed to be shared with HIV-positive patients. This may suggest acquired infection from adult parent who was already infected with a polymorphic HCMV pUL27 genotype, which is also found in HIV-infected group.
K90N was the most common HCMV pUL27 polymorphism ( Table 1 ) . In previous studies on clinical and laboratory strains exposed to MBV, there were no reports of this mutation [12] , suggesting it does not occur due to drug pressure, but its occurrence may be the cause of viral adaptation. In addition, polymorphisms K90, K96, and R107 in this study have been reported previously in laboratory and clinical CMV isolates, but not as GCV resistant [12] .
Polymorphisms found in this report are not located in any predicted pUL27 conserved domains. But as N-terminal domain of pUL27 has hydrophobic conserved residues, these variations may have a potential role in pUL27 interaction with itself or other viral/host counterparts [12] .
Our results show some other polymorphisms, which were reported to be MBV susceptible like K89 [19] . Others were Q54E/L, D123N, V103A, L56P, L60R, P62Q, L32I, and R34S, which are reported for the first time in this study. However, N-terminal polymorphisms found in this study like Q54 and L56 are close to those found in recently published study by Houldcroft et al. [18] . Polymorphisms in N-terminal hydrophobic domain may influence viral interactions.
The size of PCR products was one of our disadvantages, as single PCR product could not encompass all UL27 coding regions. This issue did not allow us to find out if there were any mutations in the C-terminal domain of UL27, which is important for pUL27 nuclear and/or nucleoli localization and egress. Further studies could resolve this issue and focus on pUL27 function in the setting of HIV-CMV co-infection.
Conclusions
Our results have clearly shown that a wide range of pUL27 polymorphisms exist, some of which have previously been reported in HIV-positive patients. In a parallel work, we investigated pUL97 polymorphism in both groups [20] and found that there are significantly more polymorphisms in pUL97 from congenitally infected neonates than from HIV-positive adults. It seems both immune system pressure and viral interactions may be involved in pUL27 sequence variation. We suggest that HCMV infection occurs at a young age in our population and during persistent infection, viral protein pUL27 variation may occur as a result of HCMV adaptation to the host.
